Literature DB >> 24674407

Growth abnormalities of the spine after radiation therapy: Respecting the past while moving forward in proton craniospinal irradiation.

Kevin McMullen1, Jeffrey Buchsbaum2, James Douglas2, Mark McDonald2, Peter Johnstone2.   

Abstract

Modern techniques of craniospinal radiation therapy (CSI) offer the advantage of modulating dose distribution to normal tissues in children and young adults. Reducing risks for second neoplasms and late effects to uninvolved tissues must be a priority for radiation oncologists. This manuscript reviews potential advantages and concerns moving forward with proton beam CSI.
Copyright © 2013 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID: 24674407     DOI: 10.1016/j.prro.2012.10.006

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  4 in total

1.  Early Axial Growth Outcomes of Pediatric Patients Receiving Proton Craniospinal Irradiation.

Authors:  Brian De; Oren Cahlon; Kevin Sine; Dennis Mah; Eugen B Hug; Suzanne L Wolden
Journal:  J Pediatr Hematol Oncol       Date:  2018-11       Impact factor: 1.289

2.  Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in Craniospinal Irradiation in Growing Pediatric Patients.

Authors:  Drosoula Giantsoudi; Joao Seco; Bree R Eaton; F Joseph Simeone; Hanne Kooy; Torunn I Yock; Nancy J Tarbell; Thomas F DeLaney; Judith Adams; Harald Paganetti; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-01       Impact factor: 7.038

3.  Practice Patterns Among Radiation Oncologists Treating Pediatric Patients With Proton Craniospinal Irradiation.

Authors:  Sara Medek; Brian De; Luke Pater; John Breneman; Anita Mahajan; Suzanne Wolden; Ralph E Vatner
Journal:  Pract Radiat Oncol       Date:  2019-07-04

4.  Clinical Implementation of Robust Optimization for Craniospinal Irradiation.

Authors:  Alexandria Tasson; Nadia N Laack; Chris Beltran
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.